However, given the small sample size in the group with LDH levels ≥ 1.5 × ULN at day 183, the differences among the three groups were marginally non-significant at a 5% confidence level.
← all excerpts
Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.
1
—
—